| Name | Title | Contact Details |
|---|---|---|
Vinay Gidwaney |
Head of Technology | Profile |
Brooks Memorial Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Brooks Memorial Hospital is based in Dunkirk, NY. You can find more information on Brooks Memorial Hospital at www.brookshospital.org
Drive tangible savings to your bottom line in weeks versus months using Valify, the only SaaS analytics and benchmarking tool for Purchased Services. Leave manual data aggregation behind. Automate the discovery of opportunity and begin tracking performance so your team can focus on realizing savings.
Hoosier is a Corona, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hospital Billing and Collection Services is a New Castle, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.